Beijing Cancer Hospital

TechObserver.in brings latest news updates from the world of technology, e-governance, enterprise IT, startups, telecom and consumer electronics.

JHL Biotech begins phase III study of JHL1101 on large B-Cell Lymphoma

JHL Biotech said that the first patient at Beijing Cancer Hospital has been successfully randomized in the Phase III study of JHL1101 to treat diffuse large B-cell lymphoma (DLBCL).
- Advertisement -SAP Hana